- Reported transaction lines
- 10
- Buy lines
- 0
- Sell lines
- 1
Filing activity by month
Original filing lines in up to 12 months with activity.
- 2026-1110
Frequently disclosed stocks
Disclosure history
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source |
|---|---|---|---|---|---|---|
| Farrell Michael J. Chairman and CEO · Director · RESMED INC | RMD RESMED INC | Other transactionFiling detailsSEC transaction code F ResMed Common Stock · Direct ownership · Reported balance after transaction: 491729 · Securities delivered or withheld for tax or exercise payment · Disposition to issuer for tax withholding on vesting of performance-based restricted stock units granted on 11/16/2023. | 2026-11-19 | 2026-11-20 | 28,180.245 shares/units | SEC 4 |
| Farrell Michael J. Chairman and CEO · Director · RESMED INC | RMD RESMED INC | Equity grant or awardFiling detailsSEC transaction code A ResMed Common Stock · Direct ownership · Reported balance after transaction: 519910 · Represents performance-based restricted stock units granted on November 16, 2023. The shares were earned on November 19, 2026, when the compensation and leadership development committee certified that the performance metrics were met for this portion of the grant. | 2026-11-19 | 2026-11-20 | 48,136 shares/units | SEC 4 |
| Farrell Michael J. Chairman and CEO · Director · RESMED INC | RMD RESMED INC | Other transactionFiling detailsSEC transaction code F ResMed Common Stock · Direct ownership · Reported balance after transaction: 471774 · Securities delivered or withheld for tax or exercise payment · Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2025. · Includes 82.2684 shares of Resmed stock purchased on Oct 30, 2026 through the Resmed Employee Stock Purchase Plan. | 2026-11-11 | 2026-11-13 | 2,435.843 shares/units | SEC 4 |
| Farrell Michael J. Chairman and CEO · Director · RESMED INC | RMD RESMED INC | Other transactionFiling detailsSEC transaction code F ResMed Common Stock · Direct ownership · Reported balance after transaction: 474209 · Securities delivered or withheld for tax or exercise payment · Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024. | 2026-11-11 | 2026-11-13 | 2,209.793 shares/units | SEC 4 |
| Farrell Michael J. Chairman and CEO · Director · RESMED INC | RMD RESMED INC | Other transactionFiling detailsSEC transaction code F ResMed Common Stock · Direct ownership · Reported balance after transaction: 476419 · Securities delivered or withheld for tax or exercise payment · Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. | 2026-11-11 | 2026-11-13 | 3,465.749 shares/units | SEC 4 |
| Farrell Michael J. Chairman and CEO · Director · RESMED INC | RMD RESMED INC | Exercise or conversionFiling detailsSEC transaction code M ResMed Common Stock Options · Derivative security · Direct ownership · Reported balance after transaction: 0 · The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. · Represents date options first become exercisable. Options vest 1/3 per year | 2026-11-09 | 2026-11-12 | 4,310 shares/units | SEC 4 |
| Farrell Michael J. Chairman and CEO · Director · RESMED INC | RMD RESMED INC | Exercise or conversionFiling detailsSEC transaction code M ResMed Common Stock Options · Derivative security · Direct ownership · Reported balance after transaction: 4310 · The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. · Represents date options first become exercisable. Options vest 1/3 per year | 2026-11-09 | 2026-11-12 | 683 shares/units | SEC 4 |
| Farrell Michael J. Chairman and CEO · Director · RESMED INC | RMD RESMED INC | SellFiling detailsSEC transaction code S ResMed Common Stock · Direct ownership · Reported balance after transaction: 479803 · SEC code covers open-market or private transactions · The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. · This transaction was executed in multiple trades at prices ranging from $231.7956 - $237.600. The price reported above reflects the weighted average sale price. | 2026-11-09 | 2026-11-12 | ≈ $1,175,089.07 4,993 shares/units | SEC 4 |
| Farrell Michael J. Chairman and CEO · Director · RESMED INC | RMD RESMED INC | Exercise or conversionFiling detailsSEC transaction code M ResMed Common Stock · Direct ownership · Reported balance after transaction: 484796 · The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. | 2026-11-09 | 2026-11-12 | 4,310 shares/units | SEC 4 |
| Farrell Michael J. Chairman and CEO · Director · RESMED INC | RMD RESMED INC | Exercise or conversionFiling detailsSEC transaction code M ResMed Common Stock · Direct ownership · Reported balance after transaction: 480486 · The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. | 2026-11-09 | 2026-11-12 | 683 shares/units | SEC 4 |
Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.